Overview

Safety and Efficacy Study of the Investigational Drug Pagoclone, in the Treatment of Persistent Developmental Stuttering (PDS)

Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
This is a research study of the investigational drug, Pagoclone, in the treatment of persistent developmental stuttering (PDS), which includes frequent repetitions or prolongations of sounds or syllables or words, or frequent hesitations or pauses that disrupt the flow of speech. Pagoclone is an investigational drug, so it is not approved by the United States Food and Drug Administration.
Phase:
Phase 2
Details
Lead Sponsor:
Pharmacology Research Institute